Business Description
Grand Pharmaceutical Group Ltd
ISIN : BMG210A71016
Total Employee Number:
12,614Compare
Compare
Traded in other countries / regions
00512.Hong KongMX6A.Germany IPO Date
2019-09-25Description
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.44 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | 2.85 | |||||
Interest Coverage | 10.37 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.21 | |||||
Beneish M-Score | -2.26 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.1 | |||||
3-Year EBITDA Growth Rate | -9.5 | |||||
3-Year EPS without NRI Growth Rate | -12.2 | |||||
3-Year FCF Growth Rate | -44.8 | |||||
3-Year Book Growth Rate | 6.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.14 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.35 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.14 | |||||
Quick Ratio | 0.93 | |||||
Cash Ratio | 0.28 | |||||
Days Inventory | 94.44 | |||||
Days Sales Outstanding | 63.4 | |||||
Days Payable | 102.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 33.2 | |||||
3-Year Average Share Buyback Ratio | 0.5 | |||||
Shareholder Yield % | 2.61 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 55.2 | |||||
Operating Margin % | 13.71 | |||||
Net Margin % | 10.1 | |||||
EBITDA Margin % | 13.49 | |||||
ROE % | 7.35 | |||||
ROA % | 4.73 | |||||
ROIC % | 6.07 | |||||
3-Year ROIIC % | -23.52 | |||||
ROC (Joel Greenblatt) % | 34.83 | |||||
ROCE % | 8.56 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.87 | |||||
Forward PE Ratio | 7.43 | |||||
PE Ratio without NRI | 11.63 | |||||
Shiller PE Ratio | 9.97 | |||||
Price-to-Owner-Earnings | 18.13 | |||||
PS Ratio | 1.3 | |||||
PB Ratio | 0.94 | |||||
Price-to-Tangible-Book | 1.38 | |||||
Price-to-Free-Cash-Flow | 123.51 | |||||
Price-to-Operating-Cash-Flow | 9.7 | |||||
EV-to-EBIT | 11.36 | |||||
EV-to-EBITDA | 11.36 | |||||
EV-to-Revenue | 1.53 | |||||
EV-to-FCF | 147.72 | |||||
Price-to-Projected-FCF | 0.59 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
Earnings Yield (Greenblatt) % | 8.8 | |||||
FCF Yield % | 0.8 | |||||
Forward Rate of Return (Yacktman) % | 6.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CGPHF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grand Pharmaceutical Group Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0 - 0 | ||
| Shares Outstanding (Mil) | 3,501.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grand Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grand Pharmaceutical Group Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| HKD 0.169000 Cash Dividend | 2026-06-12 | -- | ||
| HKD 0.260000 Cash Dividend | 2025-04-14 | -- |
Show
Entries
Grand Pharmaceutical Group Ltd Frequently Asked Questions
What is Grand Pharmaceutical Group Ltd(CGPHF)'s stock price today?
The current price of CGPHF is $0.00. The 52 week high of CGPHF is $0.00 and 52 week low is $0.00.
When is next earnings date of Grand Pharmaceutical Group Ltd(CGPHF)?
The next earnings date of Grand Pharmaceutical Group Ltd(CGPHF) is .
Does Grand Pharmaceutical Group Ltd(CGPHF) pay dividends? If so, how much?
Grand Pharmaceutical Group Ltd(CGPHF) does not pay dividend.
Guru Commentaries on OTCPK:CGPHF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Grand Pharmaceutical Group Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers